Abeona Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Abeona Therapeutics

14/03/2025 13:08

Abeona Therapeutics Inc ABEO.OQ ABEO.O is expected to show a rise in quarterly revenue when it reports  results on March 17 (estimated) for the period ending December 31 2024

The Cleveland Ohio-based  company is expected to report revenue of $100 thousand, according to the mean estimate from 5 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Abeona Therapeutics Inc is for a loss of 35 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Abeona Therapeutics Inc is $15.50‚Äč, above‚Äč its last closing price of $5.28. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.41
-0.40
-0.63
Missed
-55.9
Jun. 30 2024
-0.39
-0.36
0.19
Beat
152.2
Mar. 31 2024
-0.51
-0.51
-1.16
Missed
-126‚Äč
Dec. 31 2023
-0.47
-0.77
Missed
-63.8
‚Äč‚ÄčSep. 30 2023
-0.53
-0.53
-0.48
Beat
8.9
Jun. 30 2023
-0.71
-0.68
-0.92
Missed
-35.3‚Äč
Mar. 31 2023
-0.62
-0.58
-0.54
Beat
6.9
Dec. 31 2022
-0.75
1.53
Beat
304

This summary was machine generated March 14 at 13:08 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)